Trial Profile
A study evaluating effectiveness of ledipasvir/sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: Data from Georgian hepatitis C elimination program.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 14 Apr 2018 Results (n=20,066; As of April 30, 2017) presented at The International Liver Congress 2018
- 13 Nov 2017 New trial record
- 24 Oct 2017 Results (n=1588; As of December 31, 2016) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases